Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Synovial Sarcoma, Myxoid Liposarcoma
Interventions: Non-conforming afamitresgene autoleucel; Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years and older
U.S. locations: 11
States / cities: Phoenix, Arizona • Stanford, California • Jacksonville, Florida + 7 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Chemotherapy, SBRT, Surgical Resection; Drug · Radiation · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Baltimore, Maryland • Bel Air, Maryland • Glen Burnie, Maryland

Conditions: Traumatic Brain Injury
Interventions: Multivitamin Supplement intervention; Dietary Supplement
Lead sponsor: Amen Clinics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Rheumatoid Arthritis, Healthy Controls
Interventions: Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment; Other
Lead sponsor: Duke University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Men
Interventions: 3.4 g psyllium, 6.8 g psyllium, Meal; Dietary Supplement · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miamiville, Ohio

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: RAD001, bevacizumab; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Operating Room Scheduling
Interventions: Scheduling using historical means, Scheduling using regression modeling system; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2043
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Solid Tumors
Interventions: ORIC-114, Chemotherapy drug; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 14 more

Conditions: Cystic Fibrosis, Iron Deficiencies, Iron Deficiency Diseases
Interventions: IV Repletion, PO Repletion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Denver, Colorado • Indianapolis, Indiana • Kansas City, Kansas + 5 more

Conditions: Healthy
Interventions: Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Yogurt Intake, Gastrointestinal Immune Function, Gut Microbiome, Gut Health
Interventions: Yogurt Intervention; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Davis, California

Conditions: Contraception, Contraception Behavior
Interventions: Intervention Group, Control Group; Diagnostic Test · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 15 Years to 21 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer's Disease
Interventions: Flortaucipir F18; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 60 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Phoenix, Arizona • San Francisco, California

Conditions: Lung Diseases, Lung Cancer, Lung Diseases, Obstructive, Lung Diseases, Interstitial, Lung Inflammation
Interventions: Observational only, all subjects; measure DNA mutation and proteomic survey.; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Solid Tumors, KRAS Mutation
Interventions: BI 1823911, BI 1701963, Midazolam; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: New York, New York • Dallas, Texas • Houston, Texas

Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Interventions: asciminib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more

Conditions: Implementation Science, Diet, Food, and Nutrition, Child Care, Motor Behavior
Interventions: SAGE Basic, SAGE e-support, SAGE in-person support, Learning collaborative; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 3 Years and older
Enrollment: 871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stroke, Aphasia
Interventions: transcranial direct current stimulation; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Myopia, Refractive Errors, Contact Lens
Interventions: Single vision and multifocal contact lenses; Device
Lead sponsor: State University of New York College of Optometry; Other
Eligibility: 18 Years to 30 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Metastases
Interventions: GliaSite Radiation Therapy System; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Family History of Lung Cancer
Interventions: CT scan, Sybil; Diagnostic Test · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Keratinocyte Carcinoma, Basal Cell Carcinomas, Squamous Cell Carcinoma, Skin Cancer
Interventions: Tirbanibulin ointment 1%, non-ablative fractional laser; Drug · Device
Lead sponsor: Bruce Robinson, MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Search by objective public record fields.

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer

Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

Study to Evaluate the Effects of Psyllium on Blood Glucose

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Iron Repletion in Cystic Fibrosis

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Yogurt and GI Health

Contraception Initiation Feasibility in the Pediatric ED

18F-AV-1451 High Resolution Autopsy Study

Cough Capture as a Portal Into the Lung

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Sustainability Via Active Garden Education Wellness Implementation Strategies in Early Care and Education

Evaluating Anodal tDCS Preceding Aphasia Therapy

Peripheral Defocus Profile of Multifocal Minus Contact Lenses

GliaSite 1-3 Mets Study

LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants